Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc. (Nasdaq: ADAG) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, and this page aggregates those SEC filings for detailed review. The company submits Form 6-K current reports that incorporate press releases, financial statements, and transaction disclosures by reference into its registration statements on Form F-3 and Form S-8. These filings provide insight into Adagene’s clinical-stage operations, financing arrangements, collaborations, and risk disclosures related to its antibody-based cancer immunotherapy programs.
Within Adagene’s filings, investors can find information on its Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, and on its lead clinical program ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody in development for metastatic microsatellite-stable colorectal cancer in combination with anti-PD-1 therapy. Form 6-K reports have included financial results for specified periods, descriptions of research and development and administrative expenses, and commentary on how the company prioritizes development of ADG126. They also describe strategic transactions such as Sanofi’s agreement to make a strategic investment through Series A non-voting convertible preferred shares and the associated terms of conversion, voting, dividends, and liquidation preferences.
Adagene’s SEC submissions further document collaboration and license agreements with partners including Exelixis, Sanofi, and other counterparties, as well as borrowings from various banks and related-party transactions. These disclosures outline milestone and royalty structures, option exercises for SAFEbody discovery programs, and the use of proceeds from financing activities to support clinical development of muzastotug and other research programs.
On Stock Titan, users can access Adagene’s SEC filings as they are furnished to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain key elements of Form 6-K reports, highlight material terms in agreements, and surface information on clinical development plans, capital structure, and risk factors, allowing readers to navigate lengthy regulatory filings more efficiently.
Adagene Inc. is offering 18,666,000 ADSs, representing 23,332,500 ordinary shares. The prospectus supplement states an initial public offering price of $3.75 per ADS, for a total offering amount of $69,997,500. Net proceeds are estimated at approximately $65.3 million to fund R&D (including ADG126 and ADG138) and general corporate purposes. The supplement highlights program updates for lead candidate ADG126 (muzastotug), ongoing randomized phase 2 MSS CRC study, interim clinical data, PRC regulatory and cybersecurity risks, HFCAA/PCAOB inspection considerations, and required post-offering CSRC filings.
Adagene Inc. has priced an underwritten public offering of 18,666,000 American Depositary Shares (ADSs) at US$3.75 per ADS, for expected gross proceeds of about US$70.0 million. Each ADS represents 1.25 ordinary shares. All ADSs are being sold by the company, with closing expected on April 6, 2026, subject to customary conditions.
Leerink Partners and LifeSci Capital are acting as joint book-running managers, and Lucid Capital Markets is co‑manager. Company officers and directors agreed to a 60‑day lock‑up restricting additional share sales. The transaction is being conducted under Adagene’s effective shelf registration statement on Form F‑3 and a related prospectus supplement.
Adagene Inc. proposes an offering of American Depositary Shares (ADSs), each representing 1.25 ordinary shares, to raise proceeds to fund research and development and for general corporate purposes. The company intends to apply net proceeds primarily to R&D on pipeline programs including ADG126 and other candidates.
The prospectus supplement highlights clinical updates for muzastotug (ADG126), ongoing randomized phase 2 dosing comparisons, Fast Track designation for ADG126 plus pembrolizumab in metastatic MSS colorectal cancer without active liver metastases, and interim efficacy/safety data from multiple combination studies. The supplement also emphasizes structural and regulatory risks tied to Adagene’s Cayman holding company structure and substantive PRC operations, including cybersecurity, CSRC filing requirements and HFCAA/PCAOB inspection uncertainty.
Adagene Inc. reported updated Phase 1b/2 data for its lead CTLA-4 SAFEbody, muzastotug, in advanced microsatellite stable colorectal cancer without liver metastases, given with pembrolizumab. The combined 20 mg/kg cohorts achieved a confirmed overall response rate of 31% (8/26), versus 13% (5/39) at 10 mg/kg, and median progression-free survival of 6.7 months versus 4.8 months. Median overall survival for the 10 mg/kg cohorts was 19.8 months with 48% of patients alive at two years, while one-year survival at 20 mg/kg reached 80.8%. Safety remained manageable across 67 patients, with a 4% discontinuation rate, no dose-limiting toxicities, and no treatment-related Grade 4 or 5 events, despite higher Grade 3 TRAEs at 20 mg/kg. FDA has granted Fast Track designation for the muzastotug plus pembrolizumab combination, an ongoing randomized Phase 2 trial is enrolling with results expected in the first half of 2027, and a potential registrational study is being planned.
Adagene Inc. reported full-year 2025 results showing a sharp improvement in both operations and clinical progress. Net revenue rose to US$7.7 million from US$0.1 million, mainly from collaboration and licensing performance obligations. Research and development expenses fell 23% to US$22.0 million, reflecting prioritization of lead SAFEbody candidate muzastotug (ADG126).
Net loss attributable to shareholders narrowed to US$17.6 million from US$33.4 million, while non-GAAP net loss improved to US$13.9 million. Cash and cash equivalents were US$74.5 million as of December 31, 2025, and together with 2026 ATM proceeds, are expected to fund operations into early 2028. Clinically, muzastotug plus pembrolizumab showed a 29% confirmed overall response rate in 21 MSS colorectal cancer patients at 20 mg/kg, with a favorable tolerability profile and maturing survival tail at 10 mg/kg, supporting ongoing randomized Phase 2 and future registrational planning.
Adagene Inc., a Cayman Islands holding company with substantive operations in China and the U.S., files its annual report and reports 59,231,993 ordinary shares outstanding as of December 31, 2025. Investors hold equity in the Cayman parent, not directly in its PRC or U.S. subsidiaries.
The report emphasizes extensive PRC-related risks, including government authority to influence or restrict operations, evolving rules on offshore offerings, cybersecurity and data security, and possible limits on cross-border transfers of scientific and personal data. It also details historical PCAOB inspection limits and the risk of potential HFCAA-driven delisting if future inspections lapse.
Adagene highlights complex tax, foreign exchange and corporate law exposure in China, including potential PRC resident enterprise classification, withholding taxes on dividends and share transfers, M&A and foreign investment reviews, and SAFE registration requirements for offshore structures and employee equity plans. The company notes that changes in U.S.–China trade and investment policies could further affect funding, collaborations and its industry supply chain.
Adagene Inc. Schedule 13G filing reports that Jorey Chernett beneficially owned 2,389,060 Ordinary shares as of the close of business on March 17, 2026, representing 5.1% of the class based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025, per the issuer's prospectus.
The cover disclosure notes the CUSIP 005329107 is assigned to the issuer's ADSs quoted on NASDAQ under the symbol ADAG, and that each ADS represents one and one quarter Ordinary Share. The filing is a beneficial ownership report by the reporting person, signed on March 18, 2026.
Adagene Inc. Chief Strategy Officer Chane-Du Mickael Yannick filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 279,506 Adagene ordinary shares directly and 188,019 shares indirectly through OT Healthcare Fund I, LLC.
The filing also lists incentive stock options for 400,000 ordinary shares at an exercise price of 1.3760 per share expiring on May 13, 2035, and 400,000 performance-based options at 2.0320 per share expiring on February 5, 2036. In addition, he has indirect warrants for 250,000 shares expiring on July 3, 2028 and 250,000 shares expiring on September 2, 2028 through OT Bio Advisory, LLC.
Adagene Inc. director and Chief Financial Officer Tam Man Kin filed an initial ownership report showing direct holdings in ordinary shares and equity awards. He reports 116,583 Ordinary Shares held directly, plus 37,500 Restricted Stock Units granted under the 2021 Performance Incentive Plan, scheduled to vest in three equal installments on July 23, 2026, July 23, 2027, and July 23, 2028.
He also holds several nonqualified stock options over Adagene ordinary shares with exercise prices ranging from $1.04 to $2.032 per share and expiration dates between 2030 and 2036. Footnotes indicate which grants are time-based or performance-based and which portions are already vested and exercisable.
Adagene Inc. Chief Executive Officer Peter Luo filed an initial statement of beneficial ownership, detailing his existing equity positions in the company. The filing lists direct holdings of ordinary shares, multiple incentive stock options to acquire ordinary shares at exercise prices ranging from $1.04 to $13.85 with expirations between 2031 and 2036, and restricted stock units granted under Adagene’s equity plans. It also discloses additional options, RSUs, and ordinary shares held indirectly through his spouse. The document reports holdings only and does not show any purchases or sales.